Avoro Capital Advisors LLC boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 11.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,300,000 shares of the biotechnology company’s stock after purchasing an additional 450,000 shares during the quarter. […]
TFO Wealth Partners LLC increased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 912.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,059 shares of the biotechnology company’s stock after purchasing an additional […]
Nomura Asset Management Co. Ltd. decreased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 1.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 377,771 shares of the biotechnology company’s stock after selling 4,323 shares during the […]
Baird R W lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a hold rating in a report published on Friday morning, Zacks.com reports. BMRN has been the subject of a number of other reports. Morgan Stanley lowered their price objective on BioMarin Pharmaceutical from $115.00 to $112.00 and set […]
Robert W. Baird downgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from an outperform rating to a neutral rating in a research note released on Friday morning, Marketbeat reports. The brokerage currently has $72.00 target price on the biotechnology company’s stock, down from their previous target price of $104.00. Several other brokerages have also […]